Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (DE:DUL)
XETRA:DUL
DUL Stock Chart & Stats
Day’s Range― - ―
52-Week Range€198.70 - €400.70
Previous CloseN/A
Volume6.00
Average Volume (3M)8.00
Market Cap
$51.93B
Enterprise Value€42.48B
Total Cash (Recent Filing)$2.86B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Oct 23, 2025EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding131,079,010
10 Day Avg. Volume20
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue17.25
Enterprise Value/Gross Profit20.63
Enterprise Value/Ebitda-248.52
Forecast
1Y Price Target
$404.47Price Target Upside-0.03% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering26
Bulls Say, Bears Say
Bulls Say
Price TargetThe price target for Alnylam Pharmaceuticals is raised to $475, reflecting a positive outlook on the stock.
Regulatory DevelopmentsAlnylam Pharmaceuticals stands to benefit from the FDA's draft guidances, which broaden flexibility in clinical trial design and expand the role of real-world evidence across genetic medicines.
Sales PerformanceMonthly sales analysis suggests upside to 3Q25 Amvuttra estimates, indicating strong sales performance.
Bears Say
Clinical Trial ResultsThe opportunity for zilebesiran could be more limited after the recent phase 2 KARDIA-3 readout in hypertension, as physicians were relatively underwhelmed by the magnitude of effect in the overall population.
Compliance IssuesLow compliance in diuretics use could negatively impact ZENITH results, affecting Zilebesiran's efficacy.
Product EfficacyPhysicians were relatively underwhelmed by the magnitude of effect in the overall population for zilebesiran in hypertension, indicating potential limitations.
Alnylam Pharma News
DUL FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was €198.70 and its highest was €400.70 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $51.93B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Oct 23, 2025 which is in 9 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Jul 31, 2025. The company reported -€0.441 earnings per share for the quarter, beating the consensus estimate of -€0.47 by €0.029.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Overvalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is 0.4.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 131,079,010 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -€0.441 in its last earnings report, beating expectations of -€0.47. Following the earnings report the stock price went up 19.366%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:DUL
Alnylam Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$404.47 (-0.03% Downside)
$404.47 (-0.03% Downside)
Blogger Sentiment
Bullish
DE:DUL Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $14.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.26%
12-Months-Change
Fundamentals
Return on Equity
-257.82%
Trailing 12-Months
Asset Growth
13.88%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
DUL Company Deck
DUL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Alnylam Q2 2025 highlighted strong commercial performance and successful product launches, particularly for AMVUTTRA in ATTR-CM, leading to an upgraded financial outlook. Despite some decreases in collaboration revenue and product sales margins, the overall sentiment remains highly positive due to the robust growth and positive future guidance.View all DE:DUL earnings summariesDUL Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
DUL Stock 12 Month Forecast
Average Price Target
€404.47
▼(-0.03% Downside)
Technical Analysis
Options Prices
Currently, No data available
---